header advert
Results 1 - 1 of 1
Results per page:
Orthopaedic Proceedings
Vol. 101-B, Issue SUPP_5 | Pages 67 - 67
1 Apr 2019
DesJardins J Lucas E Chillag K Voss F
Full Access

Background

Clinical and anatomical complications from total knee replacement (TKR) procedures are debilitating, and include weakness, damage, and the loss of native anatomy. As the annual number of primary TKR surgeries in the United States has continued to rise, to a projected 3.48 million in 2030, there has been a concomitant rise in revision surgery. Damage to or loss of native knee anatomy as a result of TKR revision can leave the patient with irreversible knee dysfunction, which is a contra-indication for most TKR systems on the market. This leaves the multi-revision patient with limited medical options. Complete fusion of the joint, known as arthrodesis, is indicated in some cases. Arthrodesis is also commonly indicated for traumatic injury, bone loss, quadriceps extensor mechanism damage, and osteosarcoma. While this treatment may resolve pain and allow a patient to walk, the inability to flex the knee results in considerable functional complications. Patients with arthrodesis are unable to drive, sit in close-quarter spaces, or engage in a significant number of activities of daily living.

Product Statement

The authors have developed and patented the Engage Knee System, a novel TKR system that allows a patient to lock and unlock the knee joint by means of a handheld, non-invasive device. An internal locking mechanism is constructed of materials that have been used in orthopedic joint replacements that have been approved through the FDA 510(k) process. A lightweight, handheld magnetic device is used to actuate the locking mechanism. No percutaneous components are required or present. This device allows a patient to lock their knee joint in full extension to ambulate with the functional equivalence of an arthrodesis, but allows a patient to unlock the device and bend the knee to engage in passive activities that would be otherwise difficult or impossible. The IP portfolio for this technology is owned by Clemson University, and they are seeking a partner/licensee to pursue further technology development and validation.